Phycocyanin is a protein, and no published human pharmacokinetic study documents what remains of it after digestion. The meta-analyses behind its reputation were run on whole spirulina, a biomass in which it is only one component. The blue pigment is nonetheless enjoying rapid popularity, carried by coloured drinks, concentrated ampoules and one laboratory argument repeated with confidence. The gap between what has been measured and what is being advertised deserves to be mapped, molecule by molecule and trial by trial.
A coloured protein, and a pigment that does not detach from it
This molecule belongs to the phycobiliprotein family, the proteins that capture light in cyanobacteria. It is the most abundant protein in Arthrospira platensis, the cyanobacterium sold under the name spirulina, and the food industry has long used it as a colourant (PubMed ).
Its colour does not come from the protein itself, but from a small molecule attached to it: phycocyanobilin, a pigment from the same chemical family as bilirubin. That architectural detail governs everything that follows. Phycocyanobilin is bound to the protein by a covalent bond, meaning a sharing of electrons between two atoms, the strongest kind of bond in the chemistry of living things (PubMed ). The pigment does not come away from its carrier on its own.
In dried spirulina, that phycocyanobilin accounts for at most 1 % of the weight (PubMed ). The rest of the mass sold as phycocyanin is protein, and extraction material.
The molecule is also fragile. A 2026 review devoted to its industrial production states the constraint plainly: the application scope of phycocyanin remains limited by its poor stability and its sensitivity to temperature, light and pH (PubMed ). A sizeable share of the published research on this compound addresses not its biological effects but the means of stopping it from degrading in a jar or a bottle, through encapsulation, crosslinking or binding to other proteins.
An ingested protein normally follows a known path. Enzymes in the stomach and the intestine cut it into fragments, then into amino acids, which are absorbed as such. That is the fate of the vast majority of dietary proteins, and nothing in the structure of phycocyanin suggests it escapes. The question then becomes precise: what crosses the intestinal wall, and in what form?
The human evidence concerns whole spirulina
Spirulina itself rests on a real clinical base. A dose-response meta-analysis, appraised with the GRADE method that rates the confidence placed in a body of results, pooled 20 studies and 1,076 participants. Supplementation lowered LDL cholesterol, total cholesterol and triglycerides, and raised HDL slightly (PubMed ).
On blood pressure, a 2025 meta-analysis also appraised with GRADE reports a mean reduction of 4.41 mmHg in systolic pressure and 2.84 mmHg in diastolic pressure, with a confidence level its authors describe as moderate. The effect persists in the hypertensive, overweight and over-50 subgroups, and beyond eight weeks of intervention (PubMed ).
Mean reduction reported by a 2025 meta-analysis on complete spirulina. No equivalent figure exists for isolated phycocyanin.
These numbers are often recycled to sell phycocyanin. The slide is a quiet one, and it does not hold. Spirulina is a biomass: mostly protein, but also fatty acids including gamma-linolenic acid, phenolic compounds, iron, beta-carotene and B-group vitamins. Crediting a clinical result to one of its constituents requires testing that constituent alone against a placebo, in the same population. The meta-analyses cited do not do this, and make no claim to.
The clearest illustration comes from a competitor. A commercial extract of the same alga, enriched in bacterial lipoproteins known as Braun-type rather than in phycocyanin, was tested in about ten healthy volunteers and credits that family of molecules with a rise in the activity of natural killer cells, a type of lymphocyte belonging to innate defence (PubMed ). Two manufacturers extract two different fractions from the same cyanobacterium, and each credits its own. Marketing cannot settle the matter.
What the trials on the isolated molecule measured
What is most often presented as the clinical proof of phycocyanin is a safety trial. Twenty-four men and women received 2.3 g per day of an aqueous extract rich in phycocyanin, around 1 g of phycocyanin, for two weeks, double-blind, where neither the participant nor the caregiver knows who receives the product and who receives the placebo. The endpoint, meaning what the trial declared in advance that it would measure, concerned coagulation and platelet activation. On that point the result is reassuring: no change in coagulation markers or in platelet activation (PubMed ).
Its authors also report a reduction in chronic pain and a drop in liver transaminases, which they read as an improvement in liver function. Those observations are secondary, measured over two weeks in twenty-four people, in a trial whose authors belong to the analytical laboratory and to the company that sells the extract. A well-run safety trial establishes tolerance; it does not turn an exploratory signal into a demonstrated benefit.
On the performance side, a Polish trial followed 19 rowers from the national team, split into two groups, on 1,500 mg of spirulina extract for six weeks. The results concern ratios between lymphocyte subpopulations before and after a 2,000 m ergometer test. The authors conclude that supplementation might protect against an exercise-related immune deficit, and the title of their paper announces honestly what the work was: an attempt to induce an effect (PubMed ). No clinical outcome was measured, only intermediate cellular markers.
The best-designed trial in this file remains to be read. A French hospital consortium published in 2023 the protocol of a randomised trial, where a draw decides who receives the product, double-blind, multicentre and against a placebo. It evaluates a phycocyanin extract in the prevention of neuropathy induced by oxaliplatin-based chemotherapy (PubMed ). That is the right way to ask the question. The protocol describes the invoked mechanism for what it is, one of the possible hypotheses. Its results have not been published to date.
The missing link: what reaches the target
That leaves the mechanism, and it repays reading at source. The argument that circulates most widely holds that phycocyanobilin inhibits NADPH oxidase, an enzyme that produces free radicals, and that it thereby acts on inflammation and neurodegeneration. That argument comes from a 2010 paper published in Medical Hypotheses, a journal whose stated purpose is to host hypotheses ahead of their verification.
Its own abstract is explicit about its status. The possibility that orally administered phycocyanobilin reaches brain tissue at sufficient concentrations is presented there as consistent with the findings of two rodent studies (PubMed ). A possibility consistent with two animal studies is a legitimate research lead. Sixteen years later, it is quoted as established fact on supplement labels.
What is missing is not one more study on cultured cells: the literature holds hundreds, and recent work continues to probe this compound on intestinal and liver organoids, three-dimensional cultures that mimic an organ. What is missing is the simplest measurement of all. Give phycocyanin to volunteers, draw their blood, and report what is in it. A systematic search of the bibliographic databases returns no publication of that kind, for the protein or for its pigment.
An absence of data is not a refutation, and presenting it as one would be dishonest. Phycocyanin could clear that first filter tomorrow, through a plasma measurement in humans, through a dosage form that shields the pigment from digestion, or through controlled release of phycocyanobilin in an absorbable form. The recent history of precision nutrition is made of such rehabilitations by sourcing: a molecule blocked at absorption sometimes gives way to its precursor, which does reach the target.
For now, the blue pigment occupies an uncomfortable position. It has become the selling point of an alga whose measured benefits belong to the whole, and it rests on a mechanism published as a hypothesis. The next useful piece of information on this file will not come from another narrative review. It will come from a trial like PROPERTY, or from a blood concentration curve.
Frequently asked questions
References
- Citi V, Torre S, Flori L, et al. Nutraceutical Features of the Phycobiliprotein C-Phycocyanin: Evidence from Arthrospira platensis (Spirulina). Nutrients. 2024;16(11):1752. (PubMed )
- Liang R, Sanjeewa KKA, Mao X, Wang L. Trends in the Promising Functional Pigment, Phycocyanobilin: Preparation, Health Benefits, and Utilization. J Agric Food Chem. 2026;74(33):25783-25803. (PubMed )
- McCarty MF, Barroso-Aranda J, Contreras F. Oral phycocyanobilin may diminish the pathogenicity of activated brain microglia in neurodegenerative disorders. Med Hypotheses. 2010;74(3):601-605. (PubMed )
- Zhang AH, Zhao Z, Wu C, et al. Production, Purification, and Stabilization of Phycocyanin: Optimizing Laboratory Processes and Expanding Industrial Applications. Microb Physiol. 2026;36(1):49-64. (PubMed )
- Rahnama I, Arabi SM, Chambari M, et al. The effect of Spirulina supplementation on lipid profile: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials. Pharmacol Res. 2023;193:106802. (PubMed )
- Shiri H, Yasbolaghi Sharahi J, Alizadeh Sani M, et al. The Effect of Spirulina Supplementation on Blood Pressure in Adults: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials. Phytother Res. 2025;39(1):397-412. (PubMed )
- Nielsen CH, Balachandran P, Christensen O, et al. Enhancement of natural killer cell activity in healthy subjects by Immulina, a Spirulina extract enriched for Braun-type lipoproteins. Planta Med. 2010;76(16):1802-1808. (PubMed )
- Jensen GS, Drapeau C, Lenninger M, Benson KF. Clinical Safety of a High Dose of Phycocyanin-Enriched Aqueous Extract from Arthrospira (Spirulina) platensis: Results from a Randomized, Double-Blind, Placebo-Controlled Study with a Focus on Anticoagulant Activity and Platelet Activation. J Med Food. 2016;19(7):645-653. (PubMed )
- Juszkiewicz A, Basta P, Petriczko E, et al. An attempt to induce an immunomodulatory effect in rowers with spirulina extract. J Int Soc Sports Nutr. 2018;15:9. (PubMed )
- Le Gouill-Jaijarat C, Péréon Y, Leroy M, et al. PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE during oxaliplatin-based chemotherapy. Trials. 2023;24(1):50. (PubMed )
